|
Symbol
|
AWSBIL | ZYALTQ | SKS4LK | OVCRCH | OZTRCH | Z0A4JZ | AANOTQ | ABVHSQ | AYSBIL | LXORLK | Z0ATYZ | CQWBKB | ACDQTQ | RMAKRV | RMAG0V | Z0B7EZ | UJERWU | LZPRCH | RMBGJV | RMBU5V |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Multi Reverse Convertible | Multi Reverse Convertible | LUKB Softcallable Multi Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Callable Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Multi Reverse Convertible | Multi Reverse Convertible | Reverse Convertible | LUKB Multi Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Reverse Convertible | Multi Reverse Convertible | Autocallable Multi Vonti | Autocallable Multi Vonti | Autocallable Reverse Convertible Defensive worst | GOAL | Worst of Callable Reverse Convertible | Multi Vonti | Multi Vonti |
|
Sous-jacent
|
Compagnie Financière Richemont SA / Logitech International SA / Sika AG / Straumann Hldg. AG | Givaudan / Sonova Hldg. AG / Straumann Hldg. AG | Julius Baer Group / Roche AG / Straumann Hldg. AG | Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Kühne & Nagel Intl. AG / Straumann Hldg. AG / VAT Group | ABB / Holcim/Amrize Basket / Straumann Hldg. AG | Adecco Group AG / OC Oerlikon N / Straumann Hldg. AG / VAT Group | Baloise N / Sandoz Group AG / Sika AG / Straumann Hldg. AG | Alcon / Sonova Hldg. AG / Straumann Hldg. AG / Ypsomed Hldg. AG | Givaudan / Julius Baer Group / Straumann Hldg. AG | Alcon / Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Lonza Group N / Novartis N / Roche GS / Straumann Hldg. AG | Adecco Group AG / Logitech International SA / Stadler Rail AG / Straumann Hldg. AG / UBS Group AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Alcon / Straumann Hldg. AG / Ypsomed Hldg. AG | Bachem Hldg. AG / Lonza Group N / Straumann Hldg. AG | SGS S.A. Ltd. / Sika AG / Straumann Hldg. AG | Alcon / Lonza Group N / Novartis AG / Straumann Hldg. AG | Lonza Group N / Novartis AG / Straumann Hldg. AG / Ypsomed Hldg. AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
23.10.2026 | 02.11.2026 | 10.07.2026 | 09.06.2026 | 07.04.2026 | 30.03.2026 | 27.09.2029 | 07.10.2026 | 22.04.2027 | 05.03.2027 | 05.03.2027 | 13.03.2028 | 21.03.2030 | 24.06.2026 | 24.06.2026 | 10.12.2026 | 02.08.2027 | 07.08.2029 | 19.08.2027 | 22.02.2027 |
| Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
67,184 | 2 733,78 | 184,50 | 76,59 | 301,07 | 64,7878 | 2,8795 | 90,285 | 90,86 | 41,9958 | 96,018 | 200,5388 | 74,3275 | 90,77 | 86,26 | 54,7872 | 390,663 | 150,75 | 75,92 | 413,20 |
| rendement max. p.a. | 8,68% | 17,75% | 13,39% | 20,38% | 35,44% | 40,38% | 13,60% | - | 20,86% | 12,30% | 18,55% | 7,50% | 9,70% | 39,41% | 30,47% | 20,67% | 12,04% | 7,70% | 8,10% | 11,32% |
| Demande | - | 89,62 | - | - | 91,14 | - | - | - | - | - | - | 95,25 | 85,17 | 85,80 | 89,40 | - | 89,90 | - | 96,60 | 91,90 |
| Offre | - | 90,42 | - | - | 91,94 | - | - | - | - | - | - | 96,05 | 85,97 | 86,60 | 90,20 | - | 90,90 | - | 97,40 | 92,71 |